Promoting Overseas Development and Commercialization of Pipeline Products Hengrui Established Luzsana Subsidiary

On May 18, 2022, according to Endpoint news, Hengrui Medicine established a wholly-owned subsidiary, Luzsana Biotechnology, responsible for the internationalization (overseas development and commercialization) of Hengrui Medicine's pipeline products.

Hengrui will incorporate a portion of its assets into Luzsana, which will be exclusively responsible for drug development and commercialization in markets outside of China, currently involving more than 250 clinical studies covering oncology, cardiovascular, metabolism/diabetes, pain management, immunity, liver Areas where clinical needs such as kidney disease are met.

It is understood that the name Luzsana comes from "la luz", which means light in Spanish, and "sana", which means healing in Latin. Luzsana Biotechnology has offices in Tokyo, Basel, Switzerland, Princeton, New Jersey, etc., more than 120 employees, and CEO Scott Filosi. Scott Filosi will join Hengrui in 2021 as the CEO of Hengrui America/Europe and is responsible for the overall operation and management of Hengrui America and Europe.

Scott Filosi mentioned that Luasana's budget will not be disclosed, but will initially promote the internationalization of 11 oncology projects. Regarding overseas regulators, especially the FDA, who are not positive that Chinese data support the listing application, Scott Filosi expressed confidence in Hengrui's pipeline and data.

It is worth noting that on May 12, Hengrui announced an international good news, camrelizumab + apatinib vs sorafenib first-line treatment of unresectable or metastatic patients who have not received systemic therapy before. The international multicenter, phase III SHR-1210-III-310 study in patients with hepatocellular carcinoma met its primary endpoint.